Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Integra Lifesciences Holdings (IART) Cost of Revenue (2016 - 2025)

Integra Lifesciences Holdings' Cost of Revenue history spans 17 years, with the latest figure at $214.1 million for Q4 2025.

  • For Q4 2025, Cost of Revenue rose 10.58% year-over-year to $214.1 million; the TTM value through Dec 2025 reached $803.6 million, up 10.32%, while the annual FY2025 figure was $803.6 million, 10.32% up from the prior year.
  • Cost of Revenue for Q4 2025 was $214.1 million at Integra Lifesciences Holdings, up from $195.1 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $214.1 million in Q4 2025 and bottomed at $142.6 million in Q1 2022.
  • The 5-year median for Cost of Revenue is $163.1 million (2023), against an average of $168.7 million.
  • The largest annual shift saw Cost of Revenue skyrocketed 43.41% in 2021 before it dropped 5.32% in 2022.
  • A 5-year view of Cost of Revenue shows it stood at $156.2 million in 2021, then fell by 5.32% to $147.9 million in 2022, then increased by 15.28% to $170.5 million in 2023, then rose by 13.5% to $193.6 million in 2024, then grew by 10.58% to $214.1 million in 2025.
  • Per Business Quant, the three most recent readings for IART's Cost of Revenue are $214.1 million (Q4 2025), $195.1 million (Q3 2025), and $206.3 million (Q2 2025).